Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm, Double-Blind, Phase III, Multicenter, Randomized Clinical Trial
Journal of Palliative Medicine · 2024
DOI: 10.1089/jpm.2024.0151 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Palliative Medicine, 2024. Verfasst von Ruwani Mendis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Services, Western Health, Melbourne, Australia, Honorary Fellow, The University of Melbourne, Melbourne, Australia. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Melatonin, Neoplasms, Temazepam. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Schlaf
Abstract (Originalsprache)
Background
Sleep disturbance has a prevalence of 30–78% in patients with advanced cancer. While pharmacotherapy is common, randomized controlled studies (RCTs) investigating available agents are limited. This study examines the efficacy and safety of temazepam or melatonin versus placebo for sleep in advanced cancer.
Methods
This is a multicenter, randomized, double-blind, placebo-controlled study of temazepam, melatonin prolonged release (PR) or placebo for insomnia in patients with advanced cancer, and an insomnia severity index (ISI) score of >11.
Results
Twenty-one participants were randomized: nine to temazepam, eight to melatonin, and four to placebo. Baseline characteristics between groups were similar. The adjusted mean difference in day 8 ISI score versus placebo was −9.1 (95% confidence interval [CI] −17.5, 0.7, p = 0.04) for temazepam and −9.6 (95% CI −18,−1.2, p = 0.03) for melatonin PR. There was no improvement in global quality of life. Both agents were well tolerated.
Conclusion
Temazepam and melatonin PR were associated with a clinically significant improvement in patient-reported insomnia severity compared with placebo. Findings need confirmation with larger patient numbers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Services, Western Health, Melbourne, Australia, Honorary Fellow, The University of Melbourne, Melbourne, Australia.
- Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Melbourne Hospital Melbourne, Australia and The University of Melbourne, Melbourne, Australia.
- Department of Respiratory and Sleep Disorders Medicine, Western Health, Melbourne, Australia.
- Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Parkville, Australia.
- School of Medicine and Public Health, The University of Newcastle, NSW, Australia.
- Murdoch Children's Research Institute, Melbourne, Australia and The Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
ORCID-Profile: Aaron Wong, Jennifer Philip
Zitieren
APA
Mendis, R., Wong, A., Frenkel, S., Southcott, A. M., Selman, C. J., Martin, J., Grobler, A., Currow, D., Agar, M., Le, B., & Philip, J. (2024). Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm, Double-Blind, Phase III, Multicenter, Randomized Clinical Trial. Journal of Palliative Medicine. https://doi.org/10.1089/jpm.2024.0151
Vancouver
Mendis R, Wong A, Frenkel S, Southcott AM, Selman CJ, Martin J, et al. Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm, Double-Blind, Phase III, Multicenter, Randomized Clinical Trial. Journal of Palliative Medicine. 2024. doi:10.1089/jpm.2024.0151
BibTeX
@article{Mendis2024,
author = {Mendis, Ruwani and Wong, Aaron and Frenkel, Simon and Southcott, Anne Marie and Selman, Chris J and Martin, Jennifer and Grobler, Anneke and Currow, David and Agar, Meera and Le, Brian and Philip, Jennifer},
title = {Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm, Double-Blind, Phase III, Multicenter, Randomized Clinical Trial},
journal = {Journal of Palliative Medicine},
year = {2024},
doi = {10.1089/jpm.2024.0151}
}
EUVIMED